



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kevin P. BAKER, et al.

Application Serial No. 10/006,856

Filed: December 6, 2001

For: **SECRETED AND  
TRANSMEMBRANE  
POLYPEPTIDES AND NUCLEIC  
ACIDS ENCODING THE SAME**

) Examiner: Vogel, Nancy S.  
)  
) Art Unit: 1636  
)  
) Confirmation No: 8365  
)  
) Attorney's Docket No. 39780-2830 P1C14  
)  
) Customer No. 35489  
)  
)  
)  
)

EXPRESS MAIL LABEL NO. : EV 765 985 918 US  
DATE MAILED: November 13, 2006

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action mailed on July 13, 2006 (Paper No./Mail Date 20060707) in connection with the above-identified patent application, please enter the following amendments and consider the following arguments. This Response is timely filed with a concurrent Request for a one-month extension of time and the requisite fee.

The present Amendment and Response is further accompanied by the submission of a second Declaration under 37 C.F.R. §1.132 by Dr. Paul Polakis, and a Declaration under 37 C.F.R. §1.132 by Dr. Randy Scott. Also filed herewith is an Information Disclosure Statement providing copies of additional articles and abstracts in support of Applicants' arguments. Applicants note that some of the references listed in the Information Disclosure Statement are provided in the form of full-text articles, while others are provided as abstracts. Applicants submit that the full-text articles are provided solely because they are available to Applicants. Applicants do not intend to make any distinction among the references, or to indicate that some references in the IDS are more pertinent or material than others. Applicants

respectfully request that the information listed in the Information Disclosure Statement be considered by the Examiner and be made of record in the above-identified application.

**Amendments to the Claims** begin on page 3 of this paper.

**Remarks/Arguments** begin on page 7 of this paper.